Introduction to agentic AI in CROs

The traditional Clinical Research Organization (CRO) model is at a pivotal moment in its evolution. For decades, the industry has grappled with the increasing complexity of data by expanding headcount, yet as we approach 2026, the same inefficiencies persist. The ‘white space’ problem, characterized by inefficient time usage and departmental silos, continues to hinder clinical trial delays, a challenge that has been prevalent since the 1990s. However, technology is now enabling a fundamental restructuring of how clinical evidence is generated. By leveraging autonomous systems in CROs, we are moving closer to a streamlined, one-person CRO model with the advent of agentic AI. This evolution represents not just a technological shift but a paradigm change in clinical trial efficiency, where AI-driven CROs are set to redefine the landscape.

The role of agentic AI in transforming CROs

Agentic AI is a game-changer in the realm of clinical research. By automating routine tasks that do not require human intervention, these systems allow researchers to focus on more strategic and high-value activities. This shift is crucial in addressing the inefficiencies that have long plagued the CRO model. Agentic AI systems can manage data collection, processing, and analysis with minimal human input, significantly reducing the time and resources required for these tasks. This not only speeds up the research process but also improves the accuracy and reliability of the data collected.

Challenges in traditional CRO models

Many market research firms predict that the global CRO market will surpass $120 billion by 2030. However, these projections often overlook a growing crisis in operational efficiency. The legacy CRO model, rooted in the ‘billable hour,’ faces increasing pressure from the very complexity it was designed to manage. This inefficiency is exacerbated by a reliance on human labor, which is costly and slow to adapt to technological advancements.

Operational inefficiencies and their impact

Producing a single Clinical Study Report (CSR) or a set of Tables, Listings, and Figures (TLFs) traditionally requires massive coordination among medical writing, biostatistics, and programming teams. The resulting ‘handover delays’ and ‘QC cycles’ are not merely procedural hiccups but structural frictions inherent in a high-volume human labor model. These inefficiencies are becoming untenable as sponsors demand faster market times. The automation of Clinical Study Reports offers more streamlined solutions, reducing reliance on manual synchronization.

The cost of human labor in CROs

Human labor in CROs is not only costly but also prone to errors and inconsistencies. The traditional model relies heavily on manual processes, which are time-consuming and susceptible to human error. This can lead to delays in the research process and increase the risk of errors in data collection and analysis. As a result, the cost of conducting clinical trials can be significantly higher than necessary, putting additional financial strain on sponsors.

How agentic AI transforms CRO operations

The era of generative AI from 2023 to 2025 introduced ‘copilots’ that promised revolutionary assistance but often fell short, requiring constant human intervention. The rise of agentic AI in late 2025 marked a shift from passive assistance to autonomous execution. Unlike ‘copilots,’ today’s AI agents possess autonomy and specialized reasoning, as much or as little as the human in control allows.

Agentic AI and multi-agent systems

Modern clinical workflows are increasingly managed by multi-agent systems, which utilize specialized agents collaborating recursively. For example:

• The Data Analyst Agent: Parses protocols and raw datasets with mathematical precision, identifying trends and anomalies in real-time, enhancing clinical trial efficiency.
• The QC Agent: Conducts continuous, iterative quality control, ensuring compliance and accuracy by cross-referencing every data point against regulatory requirements.
• The Compiler Agent: Synthesizes findings into submission-ready reports, handling complex TLF-to-text conversion and summarization, reducing time and effort for regulatory submissions.
• The Master Orchestrator: Acts as the ‘manager,’ coordinating other agents, reasoning through goals, and ensuring the final output aligns with strategic objectives.

Benefits of a zero-based design

This architecture allows for a ‘zero-based design’ where workflows are built around data rather than departments, enhancing efficiency and fostering innovation through more adaptive trial designs. By focusing on data rather than departmental silos, CROs can eliminate redundant processes and improve the speed and accuracy of clinical trials. This approach also allows for greater flexibility in trial design, enabling researchers to adapt quickly to changing conditions and requirements.

Future prospects: the one-person CRO

This brings us to a question that challenges legacy executives: Can a single, highly skilled professional be a CRO? The answer is yes, albeit not yet fully realized. The technological shift is enabling a new professional profile: the Hybrid Expert. Soon, we will see the emergence of medical writer-statisticians who no longer require vast departments to execute complex tasks. By commanding an agentic workforce, a single expert can orchestrate what previously required a team of ten. From this perspective, the ‘One-Person CRO’ is not a fantasy but the next logical step in evolution.

The emergence of hybrid experts

The rise of agentic AI is paving the way for a new breed of professionals known as Hybrid Experts. These individuals possess a unique combination of skills in medical writing, statistics, and data analysis, allowing them to oversee and manage entire clinical trials with minimal support. By leveraging agentic AI systems, Hybrid Experts can automate routine tasks and focus on strategic decision-making, improving the efficiency and effectiveness of clinical trials.

Transforming the role of humans in CROs

Technology is facilitating the collapse of the ‘white space‘ paper trail between tasks. The integrated agentic stack maintains ‘departmental’ knowledge, replacing traditional handovers with continuous data flow. In this model, humans serve as the ultimate arbiters of quality and strategy, enhancing the strategic value of human oversight in clinical trials, akin to our AI Confidence Training Program.

Conclusion: embracing the change. Beyond de ‘copilot’ hype

The traditional CRO business model faces significant economic challenges. A Phase I trial can cost a sponsor between $1 million and $4 million in CRO fees alone, much of which is tied to maintaining organizational infrastructure rather than data generation. This model is increasingly unsustainable as sponsors seek more cost-effective solutions.

The shift towards AI-driven CRO efficiency

The ‘Agentic CRO’ model streamlines the traditional value proposition by eliminating unnecessary layers. Utilizing a lean, cloud-based agentic stack, these agile entities offer project-based, value-driven pricing attractive to cost-sensitive sponsors. This creates a ‘U-shaped’ market:

• The Giants: Massive firms like IQVIA and ICON will maintain their foothold by leveraging scale and infrastructure for large-scale Phase III trials.
• The Agilists: Small, agent-augmented teams or ‘One-Person CROs’ will dominate the mid-market and biotech sectors, offering speed and cost-efficiency that traditional firms struggle to match.

Adapting to a new landscape

Is the one-person CRO feasible for every trial? Not yet. However, the era of ‘billable bloat’ is ending, replaced by a model where value is defined by operational intelligence, not size. This shift towards AI-driven CROs promises greater efficiency, reduced costs, and enhanced innovation in clinical trials. As we embrace this change, CRO professionals must adapt to the new landscape shaped by agentic AI. The future of clinical research lies in the hands of those who can harness the power of technology to drive innovation and efficiency.

References

1. Grand View Research (2025). Clinical Research Organization Market Size, Share & Trends Analysis Report, 2024-2030.
2. Karunanayake N. Next-generation agentic AI for transforming healthcare. Informatics and Health. 2025 Sep 1;2(2):73-83.
3. McKinsey & Company (2025). Rewiring pharma’s regulatory submissions with AI and zero-based design.
4. Sofpromed (2025). The Ultimate Guide to Clinical Trial Costs in 2025.